Contact
searchSearch
HMP Global

Psoriasis

Featured

psoriasis0
News
Altered Lysine Crotonylation Identified in Psoriatic Skin
03/19/2026
Jessica Garlewicz
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a...
03/19/2026
The Dermatologist
psoriasis
News
Visceral Adiposity Linked to Psoriasis Risk, With Inflammation as Partial Mediator
03/11/2026
Jessica Garlewicz
Higher body roundness index, a measure of visceral adiposity, is associated with increased psoriasis prevalence, and systemic immune activation may partially mediate this relationship.
Higher body roundness index, a measure of visceral adiposity, is associated with increased psoriasis prevalence, and systemic immune activation may partially mediate this relationship.
Higher body roundness index, a...
03/11/2026
The Dermatologist
random
News
Biologic Therapy Improves Psychological Well-Being and Quality of Life in Psoriasis
03/03/2026
Jessica Garlewicz
Biologic therapy for moderate-to-severe plaque psoriasis was associated with marked improvements in psychological distress and quality of life in a real-world clinical setting.
Biologic therapy for moderate-to-severe plaque psoriasis was associated with marked improvements in psychological distress and quality of life in a real-world clinical setting.
Biologic therapy for...
03/03/2026
The Dermatologist
psoriasis
News
MicroRNA Networks Identified as Central Regulators in Psoriasis Pathogenesis
03/03/2026
Jessica Garlewicz
Psoriasis is driven by sustained inflammation and abnormal keratinocyte proliferation.
Psoriasis is driven by sustained inflammation and abnormal keratinocyte proliferation.
Psoriasis is driven by sustained...
03/03/2026
The Dermatologist
Random
News
Psychometric Study Highlights Gender Differences and Psychological Burden in Psoriasis
02/03/2026
Jessica Garlewicz
The findings reinforce the need for dermatologists to address mental health alongside physical disease severity.
The findings reinforce the need for dermatologists to address mental health alongside physical disease severity.
The findings reinforce the need...
02/03/2026
The Dermatologist
psoriasis
News
Obesity Measures Linked to Psoriasis Risk in Patients With Type 2 Diabetes, Nationwide Study Finds
02/03/2026
Jessica Garlewicz
The findings provide new insight into how obesity-related factors may influence psoriasis risk in a population already predisposed to metabolic and inflammatory comorbidities.
The findings provide new insight into how obesity-related factors may influence psoriasis risk in a population already predisposed to metabolic and inflammatory comorbidities.
The findings provide new insight...
02/03/2026
The Dermatologist
psoriasis
News
Low Prevalence but Meaningful Impact of Psychological Symptoms Seen in Well-Controlled Psoriasis
02/03/2026
Jessica Garlewicz
Anxiety and depression symptoms can still occur in young adults with well-controlled psoriasis, even when disease activity is minimal, according to a cross-sectional study exploring psychological distress and its potential biological...
Anxiety and depression symptoms can still occur in young adults with well-controlled psoriasis, even when disease activity is minimal, according to a cross-sectional study exploring psychological distress and its potential biological...
Anxiety and depression symptoms...
02/03/2026
The Dermatologist
psoriasis
News
Psoriasis Linked to Increased Atherosclerotic Risk Regardless of Arthritis Status
02/03/2026
Jessica Garlewicz
The findings reinforce psoriasis as a systemic inflammatory disease with cardiovascular implications that extend beyond joint involvement.
The findings reinforce psoriasis as a systemic inflammatory disease with cardiovascular implications that extend beyond joint involvement.
The findings reinforce psoriasis...
02/03/2026
The Dermatologist
NPF Endorsed Features
Position Statement: Routine TB Testing for IL-17 and IL-23 Inhibitors
01/30/2026
Lisa Kuhns, PhD, MD
A new NPF Medical Board/International Psoriasis Council joint position statement concludes that routine latent tuberculosis infection testing is unnecessary for patients with psoriasis who are taking IL-17 or IL-23 inhibitors.
A new NPF Medical Board/International Psoriasis Council joint position statement concludes that routine latent tuberculosis infection testing is unnecessary for patients with psoriasis who are taking IL-17 or IL-23 inhibitors.
A new NPF Medical...
01/30/2026
The Dermatologist
psoriasis
News
Real-World Registry Data Identify Predictors of Biologic Switching in Psoriasis Care
01/22/2026
Jessica Garlewicz
A new analysis from the CorEvitas Psoriasis Registry highlights baseline clinical and patient-reported features associated with switching biologic therapies in real-world practice, offering insights to support earlier, shared decision-making.
A new analysis from the CorEvitas Psoriasis Registry highlights baseline clinical and patient-reported features associated with switching biologic therapies in real-world practice, offering insights to support earlier, shared decision-making.
A new analysis from the...
01/22/2026
The Dermatologist
psoriasis
News
Mathematical Modeling Study Highlights Cytokine Balance and Stem Cell Feedback in Psoriasis Control
01/22/2026
Jessica Garlewicz
A new systems biology study using mathematical modeling provides insight into how cytokine imbalance drives psoriasis flares and suggests that restoring immune-epidermal feedback.
A new systems biology study using mathematical modeling provides insight into how cytokine imbalance drives psoriasis flares and suggests that restoring immune-epidermal feedback.
A new systems biology study...
01/22/2026
The Dermatologist

News & FDA Alerts

psoriasis0
News
Altered Lysine Crotonylation Identified in Psoriatic Skin
03/19/2026
Jessica Garlewicz
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a...
03/19/2026
The Dermatologist
random
News
Biologic Therapy Improves Psychological Well-Being and Quality of Life in Psoriasis
03/03/2026
Jessica Garlewicz
Biologic therapy for moderate-to-severe plaque psoriasis was associated with marked improvements in psychological distress and quality of life in a real-world clinical setting.
Biologic therapy for moderate-to-severe plaque psoriasis was associated with marked improvements in psychological distress and quality of life in a real-world clinical setting.
Biologic therapy for...
03/03/2026
The Dermatologist
psoriasis
News
Low Prevalence but Meaningful Impact of Psychological Symptoms Seen in Well-Controlled Psoriasis
02/03/2026
Jessica Garlewicz
Anxiety and depression symptoms can still occur in young adults with well-controlled psoriasis, even when disease activity is minimal, according to a cross-sectional study exploring psychological distress and its potential biological...
Anxiety and depression symptoms can still occur in young adults with well-controlled psoriasis, even when disease activity is minimal, according to a cross-sectional study exploring psychological distress and its potential biological...
Anxiety and depression symptoms...
02/03/2026
The Dermatologist
psoriasis
News
Mathematical Modeling Study Highlights Cytokine Balance and Stem Cell Feedback in Psoriasis Control
01/22/2026
Jessica Garlewicz
A new systems biology study using mathematical modeling provides insight into how cytokine imbalance drives psoriasis flares and suggests that restoring immune-epidermal feedback.
A new systems biology study using mathematical modeling provides insight into how cytokine imbalance drives psoriasis flares and suggests that restoring immune-epidermal feedback.
A new systems biology study...
01/22/2026
The Dermatologist
psoriasis
News
Study Links Hypothyroidism to Psoriasis, Independent of Disease Severity
09/02/2025
Jessica Garlewicz
The findings suggest that thyroid abnormalities may represent an independent comorbidity, rather than a direct consequence of psoriasis severity.
The findings suggest that thyroid abnormalities may represent an independent comorbidity, rather than a direct consequence of psoriasis severity.
The findings suggest that...
09/02/2025
The Dermatologist
psoriasis
News
Beta-Blockers Not Linked to Increased Psoriasis Risk, Study Finds
09/02/2025
Jessica Garlewicz
A new multi-method analysis challenges long-standing concerns regarding beta-blockers and their role in triggering or worsening psoriasis.
A new multi-method analysis challenges long-standing concerns regarding beta-blockers and their role in triggering or worsening psoriasis.
A new multi-method analysis...
09/02/2025
The Dermatologist
psoriasis
News
Study Finds Distinct Psychosocial Burdens in Early- vs Late-Onset Psoriasis
08/14/2025
Jessica Garlewicz
A new cross-sectional study comparing early-onset and late-onset psoriasis highlights key clinical and psychosocial differences that may inform individualized care strategies for dermatologists.
A new cross-sectional study comparing early-onset and late-onset psoriasis highlights key clinical and psychosocial differences that may inform individualized care strategies for dermatologists.
A new cross-sectional study...
08/14/2025
The Dermatologist
psoriasis
News
Study Highlights Emerging Role of Stem Cells in Psoriasis Pathogenesis
08/14/2025
Jessica Garlewicz
Psoriasis is traditionally understood as a T cell–mediated disease, driven largely by Th1 and Th17 cell activation and impaired regulatory T cell (T-reg) function.
Psoriasis is traditionally understood as a T cell–mediated disease, driven largely by Th1 and Th17 cell activation and impaired regulatory T cell (T-reg) function.
Psoriasis is traditionally...
08/14/2025
The Dermatologist
psoriasis
News
Comorbidity Patterns in Moderate-to-Severe Psoriasis Highlight Need for Integrated Clinical Management
07/22/2025
Jessica Garlewicz
By incorporating comorbidity surveillance into dermatologic care, clinicians can improve disease control, minimize therapeutic risks, and enhance overall patient quality of life.
By incorporating comorbidity surveillance into dermatologic care, clinicians can improve disease control, minimize therapeutic risks, and enhance overall patient quality of life.
By incorporating comorbidity...
07/22/2025
The Dermatologist
psoriasis
News
Early Use of Biologics in Psoriasis May Alter Inflammatory Course, Improve Comorbidities
07/10/2025
Jessica Garlewicz
As the understanding of psoriasis pathophysiology continues to evolve, treatment goals may need to expand accordingly.
As the understanding of psoriasis pathophysiology continues to evolve, treatment goals may need to expand accordingly.
As the understanding of...
07/10/2025
The Dermatologist
cream
News
Behenic Acid and Ceramide Creams Accelerate Skin Barrier Recovery
10/13/2026
Coleen Stern, MA
Creams containing behenic acid (BA) or ceramide (CER) accelerated recovery of experimentally damaged skin, suggesting that both lipid components may support topical formulations designed to restore barrier function.
Creams containing behenic acid (BA) or ceramide (CER) accelerated recovery of experimentally damaged skin, suggesting that both lipid components may support topical formulations designed to restore barrier function.
Creams containing behenic acid...
10/13/2026
The Dermatologist
FDA Alerts
FDA Approves Rhapsido as First Treatment for Symptomatic Dermographism in Adults
10/08/2026
Jessica Garlewicz
On October 7, 2026, the US Food and Drug Administration approved remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, as the first treatment for adults with symptomatic dermographism inadequately controlled by H1...
On October 7, 2026, the US Food and Drug Administration approved remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, as the first treatment for adults with symptomatic dermographism inadequately controlled by H1...
On October 7, 2026, the US Food...
10/08/2026
The Dermatologist
News
GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Risk in Patients With Psoriasis
10/07/2026
Jessica Garlewicz
Glucagon-like peptide-1 receptor agonist treatment was associated with lower all-cause mortality and reduced cardiovascular and psychiatric comorbidity risks among patients with psoriasis and obesity or diabetes.
Glucagon-like peptide-1 receptor agonist treatment was associated with lower all-cause mortality and reduced cardiovascular and psychiatric comorbidity risks among patients with psoriasis and obesity or diabetes.
Glucagon-like peptide-1 receptor...
10/07/2026
The Dermatologist
Smiling woman touching neck
News
Anatomy-Driven Model Aims to Prevent GLP-1 RA–Associated Facial Aging
10/01/2026
Coleen Stern, MA
Researchers propose an anatomy-driven framework for identifying patients at risk for rapid, region-specific facial volume loss and intervening before visible facial aging progresses.
Researchers propose an anatomy-driven framework for identifying patients at risk for rapid, region-specific facial volume loss and intervening before visible facial aging progresses.
Researchers propose an...
10/01/2026
The Dermatologist
dkin
News
Review Reframes Skin Barrier as an Integrated Defense System
09/30/2026
Coleen Stern, MA
The skin barrier functions as an interconnected physical, chemical, immune, and microbial defense system rather than a single structural layer.
The skin barrier functions as an interconnected physical, chemical, immune, and microbial defense system rather than a single structural layer.
The skin barrier functions as an...
09/30/2026
The Dermatologist
Alopecia
FDA Alerts
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
09/28/2026
Riya Gandhi, MA
FDA has expanded the indication for baricitinib (Olumiant) to include adolescents aged 12 years and older with severe alopecia areata, based on results from the Phase 3 BRAVE-AA-PEDS trial.
FDA has expanded the indication for baricitinib (Olumiant) to include adolescents aged 12 years and older with severe alopecia areata, based on results from the Phase 3 BRAVE-AA-PEDS trial.
FDA has expanded the indication...
09/28/2026
The Dermatologist
News
Global Psoriasis Burden Nearly Doubled Over 3 Decades, Economic Costs Reach $149 Billion
09/03/2026
Jessica Garlewicz
Investigators assessed trends in psoriasis cases, effects on quality of life, and associated economic costs.
Investigators assessed trends in psoriasis cases, effects on quality of life, and associated economic costs.
Investigators assessed trends in...
09/03/2026
The Dermatologist
FDA Alerts
FDA Approves Lisraya as First Oral Therapy for Adult Dermatomyositis
08/31/2026
Coleen Stern, MA
For dermatologists and patients, this approval provides a new alternative targeting the JAK-mediated inflammation that damages the muscles and skin in dermatomyositis to control both cutaneous and systemic manifestations.
For dermatologists and patients, this approval provides a new alternative targeting the JAK-mediated inflammation that damages the muscles and skin in dermatomyositis to control both cutaneous and systemic manifestations.
For dermatologists and patients,...
08/31/2026
The Dermatologist
FDA Alerts
FDA Grants Accelerated Approval to Tudriqev for PD-1-Refractory Advanced Melanoma
08/07/2026
Jessica Garlewicz
The US Food and Drug Administration (FDA) has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma.
The US Food and Drug Administration (FDA) has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma.
The US Food and Drug...
08/07/2026
The Dermatologist
roflum
FDA Alerts
FDA Approves Roflumilast Cream 0.3% for Plaque Psoriasis in Children as Young as 2 Years
06/30/2026
Riya Gandhi, MA
The expanded indication makes roflumilast cream 0.3% the first once-daily, steroid-free topical therapy approved for plaque psoriasis in children aged 2 years and older, providing a new long-term treatment option for pediatric patients.
The expanded indication makes roflumilast cream 0.3% the first once-daily, steroid-free topical therapy approved for plaque psoriasis in children aged 2 years and older, providing a new long-term treatment option for pediatric patients.
The expanded indication makes...
06/30/2026
The Dermatologist

Endorsed Articles

NPF Endorsed Features
Position Statement: Routine TB Testing for IL-17 and IL-23 Inhibitors
01/30/2026
Lisa Kuhns, PhD, MD
A new NPF Medical Board/International Psoriasis Council joint position statement concludes that routine latent tuberculosis infection testing is unnecessary for patients with psoriasis who are taking IL-17 or IL-23 inhibitors.
A new NPF Medical Board/International Psoriasis Council joint position statement concludes that routine latent tuberculosis infection testing is unnecessary for patients with psoriasis who are taking IL-17 or IL-23 inhibitors.
A new NPF Medical...
01/30/2026
The Dermatologist
Partner Approved
Unilateral Linear Psoriasis: A Case Report
05/13/2020
Sonya Zarkhin, DO; Sean Stephenson, DO
A 19-year-old white woman with a 4-year history of a rash localized to her left arm and hand. The lesion started as a small plaque on her forearm and gradually spread in a linear fashion from her fingertip to her upper arm.
A 19-year-old white woman with a 4-year history of a rash localized to her left arm and hand. The lesion started as a small plaque on her forearm and gradually spread in a linear fashion from her fingertip to her upper arm.
A 19-year-old white woman with a...
05/13/2020
The Dermatologist
Partner Approved
Disease Management and Patient Care Recommendations During the COVID-19 Pandemic
04/14/2020
Lauren Mateja
Patients with psoriasis and psoriatic arthritis have increased calls to their dermatologist for advice on continuance of their therapy during uncertain times. Guidance from national organizations provide answers that dermatologists can pass...
Patients with psoriasis and psoriatic arthritis have increased calls to their dermatologist for advice on continuance of their therapy during uncertain times. Guidance from national organizations provide answers that dermatologists can pass...
Patients with psoriasis and...
04/14/2020
The Dermatologist
NPF Endorsed Features
Options With IL-23 Inhibitors for the Patient With Psoriasis
03/12/2020
Lauren Mateja
New and emerging therapies such as biologics continue to improve quality of life and outcomes for patients with psoriasis. Biologics that block IL-23 functions present a unique opportunity to provide long-term, effective treatment.
New and emerging therapies such as biologics continue to improve quality of life and outcomes for patients with psoriasis. Biologics that block IL-23 functions present a unique opportunity to provide long-term, effective treatment.
New and emerging therapies such...
03/12/2020
The Dermatologist
Partner Approved
Management of Psoriasis in Adolescents
01/16/2020
Lauren Mateja
Psoriasis can affect patients at all walks of life, from children to the elderly. Adolescents, however, require special considerations, from psychosocial conditions to therapy options, for the short- and long-term...
Psoriasis can affect patients at all walks of life, from children to the elderly. Adolescents, however, require special considerations, from psychosocial conditions to therapy options, for the short- and long-term...
...
01/16/2020
The Dermatologist
NPF Endorsed Features
Position Statement: Routine TB Testing for IL-17 and IL-23 Inhibitors
01/30/2026
Lisa Kuhns, PhD, MD
A new NPF Medical Board/International Psoriasis Council joint position statement concludes that routine latent tuberculosis infection testing is unnecessary for patients with psoriasis who are taking IL-17 or IL-23 inhibitors.
A new NPF Medical Board/International Psoriasis Council joint position statement concludes that routine latent tuberculosis infection testing is unnecessary for patients with psoriasis who are taking IL-17 or IL-23 inhibitors.
A new NPF Medical...
01/30/2026
The Dermatologist
NPF Endorsed Features
Psoriatic Disease and the Domino Effect of Comorbidities
10/06/2025
Lisa Kuhns, PhD, MD
Research has consistently shown that people with psoriasis and psoriatic arthritis face higher rates of serious comorbidities
Research has consistently shown that people with psoriasis and psoriatic arthritis face higher rates of serious comorbidities
Research has consistently shown...
10/06/2025
The Dermatologist
NPF Endorsed Features
Salon to Skin: How Dermatologists and Hair Stylists Can Work Together
08/02/2025
Samantha Schlosser
With a passion for hair loss and ethnic skin, Dr Chesahna Kindred is bridging the gap between beauty and medicine through the S.T.R.A.N.D. Network.
With a passion for hair loss and ethnic skin, Dr Chesahna Kindred is bridging the gap between beauty and medicine through the S.T.R.A.N.D. Network.
With a passion for hair loss and...
08/02/2025
The Dermatologist
NPF Endorsed Features
Missouri’s Call, ECHO’s Answer: Expanding Access to Psoriasis Care
05/01/2025
Demi Elord, MS-II; Shivani Jain, MSIV
With continued innovation, Extension for Community Healthcare Outcomes programs have the potential to revolutionize psoriasis treatment, improving outcomes and bringing expert care closer to those who need it most.
With continued innovation, Extension for Community Healthcare Outcomes programs have the potential to revolutionize psoriasis treatment, improving outcomes and bringing expert care closer to those who need it most.
With continued innovation,...
05/01/2025
The Dermatologist
NPF Endorsed Features
Highlights From the 2024 Psoriasis Health Indicator Report
02/03/2025
Lisa Kuhns, PhD, MD
The National Psoriasis Foundation’s first-ever health indicator report takes a deep dive into the health burden of psoriatic disease, treatment gaps, and future directions in care.
The National Psoriasis Foundation’s first-ever health indicator report takes a deep dive into the health burden of psoriatic disease, treatment gaps, and future directions in care.
The National Psoriasis...
02/03/2025
The Dermatologist
NPF Endorsed Features
Reexamining Remission in Psoriasis
10/07/2024
Jess Smith, BS
Results from a recent study can inform future efforts to develop or modify definitions of remission for the psoriatic disease community.
Results from a recent study can inform future efforts to develop or modify definitions of remission for the psoriatic disease community.
Results from a recent study can...
10/07/2024
The Dermatologist
NPF Endorsed Features
Phone-a-Friend: Exploring the Collaborative Care Model in Psoriasis
08/06/2024
Samantha Koons
The multifaceted nature of psoriatic disease may require multiple providers from different disciplines or specialties for optimal patient care.
The multifaceted nature of psoriatic disease may require multiple providers from different disciplines or specialties for optimal patient care.
The multifaceted nature of...
08/06/2024
The Dermatologist
NPF Endorsed Features
What’s New in Psoriasis Research
05/03/2024
Jessica Garlewicz; Riya Gandhi, MA
Keep up-to-date with this roundup of recent studies.
Keep up-to-date with this roundup of recent studies.
Keep up-to-date with this...
05/03/2024
The Dermatologist
NPF Endorsed Features
The Mental Health and Psoriatic Disease Connection
02/07/2024
Samip Sheth, MD
A recent National Psoriasis Foundation webinar explores the link between psychiatric comorbidities and skin conditions.
A recent National Psoriasis Foundation webinar explores the link between psychiatric comorbidities and skin conditions.
A recent National Psoriasis...
02/07/2024
The Dermatologist
NPF Endorsed Features
Understanding Generalized Pustular Psoriasis
12/05/2023
Jessica Garlewicz
Proper evaluation and history collection are essential for accurate diagnosis and timely treatment.
Proper evaluation and history collection are essential for accurate diagnosis and timely treatment.
Proper evaluation and history...
12/05/2023
The Dermatologist

Quizzes and Polls

psoriasis
Quiz
Long-Term Safety of Risankizumab
10/18/2024
Jessica Garlewicz
What were the primary findings regarding the long-term safety of risankizumab?
What were the primary findings regarding the long-term safety of risankizumab?
What were the primary findings...
10/18/2024
The Dermatologist
psoriatic arthritis on hand
Quiz
Trivia: Treatment Improves Health-Related Quality of Life in Patients With Psoriatic Arthritis
08/03/2022
Jessica Garlewicz
Which treatment improved health-related quality of life, fatigue, pain, and work productivity in adults with active psoriatic arthritis?
Which treatment improved health-related quality of life, fatigue, pain, and work productivity in adults with active psoriatic arthritis?
Which treatment improved...
08/03/2022
The Dermatologist
psoriasis on hand and stomach
Quiz
Trivia: Risankizumab Comparable Safety and Efficacy Profiles in Psoriasis
06/15/2022
Jessica Garlewicz
Risankizumab’s efficacy and safety profile is faster than another anti-IL23 when treating which of these options?
Risankizumab’s efficacy and safety profile is faster than another anti-IL23 when treating which of these options?
Risankizumab’s efficacy and...
06/15/2022
The Dermatologist
psoriasis generalized pustular
Quiz
Trivia: Psoriasis Treatment Perspectives and Expectations
05/18/2022
Jessica Garlewicz
Which of these options list the characteristics that impact treatment goals for patients with psoriasis?
Which of these options list the characteristics that impact treatment goals for patients with psoriasis?
Which of these options list the...
05/18/2022
The Dermatologist
psoriasis severe arm
Quiz
Trivia: Psoriasis and Stress Coping Strategies
04/05/2022
Jessica Garlewicz
Which of the following is impacted by psoriasis and stress coping strategies ?
Which of the following is impacted by psoriasis and stress coping strategies ?
Which of the following is...
04/05/2022
The Dermatologist
psoriasis-severe
Quiz
Trivia: Unmet Needs in Psoriasis
12/02/2021
Which of the following accurately highlights what unmet needs were reported by patients with mild-to-moderate psoriasis?
Which of the following accurately highlights what unmet needs were reported by patients with mild-to-moderate psoriasis?
Which of the following...
12/02/2021
The Dermatologist
Severe psoriasis, such as plaque psoriasis shown here, can benefit from biologic agents that enable psoriasis treatment.
Quiz
Trivia: Efficacy of Biologic Agents
10/05/2021
Can you identify how dermatologists can observe the efficacy of biologic agents on the full psoriasis disease burden?
Can you identify how dermatologists can observe the efficacy of biologic agents on the full psoriasis disease burden?
Can you identify how...
10/05/2021
The Dermatologist
Patient with psoriasis on the scalp. Recent studies have looked into hypochondriasis in psoriasis such as this patient.
Quiz
Trivia: Hypochondriasis and Personality Traits in PsO
09/09/2021
An observational study of patients with psoriasis sought to assess hypochondriasis and personality traits. Can you identify which of these options describes their findings?
An observational study of patients with psoriasis sought to assess hypochondriasis and personality traits. Can you identify which of these options describes their findings?
An observational study of...
09/09/2021
The Dermatologist
A patient suffering from obesity showcasing a case of plaque psoriasis in a potential risk for cardiovascular disease.
Quiz
Trivia: Measuring Arterial Function in Patients with Psoriasis
08/26/2021
Identify what noninvasive measurement of arterial function was performed on patients with chronic plaque psoriasis to determine cardiovascular risk.
Identify what noninvasive measurement of arterial function was performed on patients with chronic plaque psoriasis to determine cardiovascular risk.
Identify what noninvasive...
08/26/2021
The Dermatologist
pediatric psoriasis pictures severe psoriasis on knees
Quiz
Trivia: Pediatric Psoriasis Comorbidities
08/23/2021
Which of these options accurately portrays the common comorbidities observed within pediatric patients with psoriasis?
Which of these options accurately portrays the common comorbidities observed within pediatric patients with psoriasis?
Which of these options...
08/23/2021
The Dermatologist
AD
Quiz
Precision Therapeutic Selection Across Type 2 Inflammatory Skin Diseases
10/15/2026
Riya Gandhi, MA
Evaluate your clinical approach to selecting targeted therapies across multiple type 2 inflammatory skin diseases by integrating disease biology, symptom burden, and treatment sequencing.
Evaluate your clinical approach to selecting targeted therapies across multiple type 2 inflammatory skin diseases by integrating disease biology, symptom burden, and treatment sequencing.
Evaluate your clinical approach...
10/15/2026
The Dermatologist
Quiz
Quiz: Efficacy Findings for Povorcitinib in the Phase 3 STOP-HS1 and STOP-HS2 Trials
10/01/2026
Jessica Garlewicz
Which of the following best describes the week 12 efficacy findings for povorcitinib in the phase 3 STOP-HS1 and STOP-HS2 trials in patients with moderate-to-severe hidradenitis suppurativa?
Which of the following best describes the week 12 efficacy findings for povorcitinib in the phase 3 STOP-HS1 and STOP-HS2 trials in patients with moderate-to-severe hidradenitis suppurativa?
Which of the following best...
10/01/2026
The Dermatologist
itch
Quiz
Clinical Implications of Type 2 Inflammation in Chronic Spontaneous Urticaria
09/21/2026
Riya Gandhi, MA
Evaluate your understanding of disease fluctuation, neuroimmune signaling, cytokine biology, and targeted therapeutic strategies in chronic spontaneous urticaria.
Evaluate your understanding of disease fluctuation, neuroimmune signaling, cytokine biology, and targeted therapeutic strategies in chronic spontaneous urticaria.
Evaluate your understanding of...
09/21/2026
The Dermatologist
random molecule
Quiz
Understanding Type 2 Inflammatory Mechanisms in Chronic Spontaneous Urticaria
09/14/2026
Riya Gandhi, MA
Test your understanding of cytokine signaling, mast cell biology, neuroimmune interactions, and the mechanisms that drive chronic spontaneous urticaria.
Test your understanding of cytokine signaling, mast cell biology, neuroimmune interactions, and the mechanisms that drive chronic spontaneous urticaria.
Test your understanding of...
09/14/2026
The Dermatologist
AD
Quiz
Pediatric AD Quiz: Biologic Therapy Challenges in Children
08/10/2026
Riya Gandhi, MA
Assess your understanding of biologic therapy in pediatric atopic dermatitis with this expert quiz. Explore practical barriers to treatment, considerations for young children and caregivers, and real-world factors that influence successful...
Assess your understanding of biologic therapy in pediatric atopic dermatitis with this expert quiz. Explore practical barriers to treatment, considerations for young children and caregivers, and real-world factors that influence successful...
Assess your understanding of...
08/10/2026
The Dermatologist
AD
Quiz
Pediatric AD Quiz: When to Escalate to Systemic Therapy
08/10/2026
Riya Gandhi, MA
Test your knowledge of treatment escalation in pediatric atopic dermatitis. This clinical quiz explores when topical therapy is no longer sufficient and when to initiate systemic treatment in children.
Test your knowledge of treatment escalation in pediatric atopic dermatitis. This clinical quiz explores when topical therapy is no longer sufficient and when to initiate systemic treatment in children.
Test your knowledge of treatment...
08/10/2026
The Dermatologist
Quiz
Type 2 Endotypes and Therapeutic Strategy in Prurigo Nodularis
06/25/2026
Riya Gandhi, MA
Assess advanced concepts in type 2 inflammatory endotypes, shared therapeutic pathways, and practical treatment approaches in prurigo nodularis.
Assess advanced concepts in type 2 inflammatory endotypes, shared therapeutic pathways, and practical treatment approaches in prurigo nodularis.
Assess advanced concepts in type...
06/25/2026
The Dermatologist
itch
Quiz
Fibrosis and Persistent Itch in Prurigo Nodularis
06/15/2026
Riya Gandhi, MA
Test your clinical understanding of fibrotic remodeling and the mechanisms underlying persistent itch and chronic disease activity in prurigo nodularis.
Test your clinical understanding of fibrotic remodeling and the mechanisms underlying persistent itch and chronic disease activity in prurigo nodularis.
Test your clinical understanding...
06/15/2026
The Dermatologist
brain
Quiz
Neuroimmune Mechanisms and Cytokine Signaling in Prurigo Nodularis
06/05/2026
Riya Gandhi, MA
Explore advanced concepts in neuroimmune communication, cytokine-driven itch amplification, and fibrotic signaling pathways involved in prurigo nodularis.
Explore advanced concepts in neuroimmune communication, cytokine-driven itch amplification, and fibrotic signaling pathways involved in prurigo nodularis.
Explore advanced concepts in...
06/05/2026
The Dermatologist
Quiz
Predicting Disease Severity and Persistence in Pediatric Atopic Dermatitis
04/15/2026
Riya Gandhi, MA
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in...
04/15/2026
The Dermatologist
october 2026

Current Issue

October 2026
Volume 34
Issue 7
Current Issue
Issue Archive

Recent News

psoriasis0
News
Altered Lysine Crotonylation Identified in Psoriatic Skin
03/19/2026
Jessica Garlewicz
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a...
03/19/2026
The Dermatologist
random
News
Biologic Therapy Improves Psychological Well-Being and Quality of Life in Psoriasis
03/03/2026
Jessica Garlewicz
Biologic therapy for moderate-to-severe plaque psoriasis was associated with marked improvements in psychological distress and quality of life in a real-world clinical setting.
Biologic therapy for moderate-to-severe plaque psoriasis was associated with marked improvements in psychological distress and quality of life in a real-world clinical setting.
Biologic therapy for...
03/03/2026
The Dermatologist
psoriasis
News
Low Prevalence but Meaningful Impact of Psychological Symptoms Seen in Well-Controlled Psoriasis
02/03/2026
Jessica Garlewicz
Anxiety and depression symptoms can still occur in young adults with well-controlled psoriasis, even when disease activity is minimal, according to a cross-sectional study exploring psychological distress and its potential biological...
Anxiety and depression symptoms can still occur in young adults with well-controlled psoriasis, even when disease activity is minimal, according to a cross-sectional study exploring psychological distress and its potential biological...
Anxiety and depression symptoms...
02/03/2026
The Dermatologist
psoriasis
News
Mathematical Modeling Study Highlights Cytokine Balance and Stem Cell Feedback in Psoriasis Control
01/22/2026
Jessica Garlewicz
A new systems biology study using mathematical modeling provides insight into how cytokine imbalance drives psoriasis flares and suggests that restoring immune-epidermal feedback.
A new systems biology study using mathematical modeling provides insight into how cytokine imbalance drives psoriasis flares and suggests that restoring immune-epidermal feedback.
A new systems biology study...
01/22/2026
The Dermatologist
psoriasis
News
Study Links Hypothyroidism to Psoriasis, Independent of Disease Severity
09/02/2025
Jessica Garlewicz
The findings suggest that thyroid abnormalities may represent an independent comorbidity, rather than a direct consequence of psoriasis severity.
The findings suggest that thyroid abnormalities may represent an independent comorbidity, rather than a direct consequence of psoriasis severity.
The findings suggest that...
09/02/2025
The Dermatologist
psoriasis
News
Beta-Blockers Not Linked to Increased Psoriasis Risk, Study Finds
09/02/2025
Jessica Garlewicz
A new multi-method analysis challenges long-standing concerns regarding beta-blockers and their role in triggering or worsening psoriasis.
A new multi-method analysis challenges long-standing concerns regarding beta-blockers and their role in triggering or worsening psoriasis.
A new multi-method analysis...
09/02/2025
The Dermatologist
psoriasis
News
Study Finds Distinct Psychosocial Burdens in Early- vs Late-Onset Psoriasis
08/14/2025
Jessica Garlewicz
A new cross-sectional study comparing early-onset and late-onset psoriasis highlights key clinical and psychosocial differences that may inform individualized care strategies for dermatologists.
A new cross-sectional study comparing early-onset and late-onset psoriasis highlights key clinical and psychosocial differences that may inform individualized care strategies for dermatologists.
A new cross-sectional study...
08/14/2025
The Dermatologist
psoriasis
News
Study Highlights Emerging Role of Stem Cells in Psoriasis Pathogenesis
08/14/2025
Jessica Garlewicz
Psoriasis is traditionally understood as a T cell–mediated disease, driven largely by Th1 and Th17 cell activation and impaired regulatory T cell (T-reg) function.
Psoriasis is traditionally understood as a T cell–mediated disease, driven largely by Th1 and Th17 cell activation and impaired regulatory T cell (T-reg) function.
Psoriasis is traditionally...
08/14/2025
The Dermatologist
psoriasis
News
Comorbidity Patterns in Moderate-to-Severe Psoriasis Highlight Need for Integrated Clinical Management
07/22/2025
Jessica Garlewicz
By incorporating comorbidity surveillance into dermatologic care, clinicians can improve disease control, minimize therapeutic risks, and enhance overall patient quality of life.
By incorporating comorbidity surveillance into dermatologic care, clinicians can improve disease control, minimize therapeutic risks, and enhance overall patient quality of life.
By incorporating comorbidity...
07/22/2025
The Dermatologist
psoriasis
News
Early Use of Biologics in Psoriasis May Alter Inflammatory Course, Improve Comorbidities
07/10/2025
Jessica Garlewicz
As the understanding of psoriasis pathophysiology continues to evolve, treatment goals may need to expand accordingly.
As the understanding of psoriasis pathophysiology continues to evolve, treatment goals may need to expand accordingly.
As the understanding of...
07/10/2025
The Dermatologist
cream
News
Behenic Acid and Ceramide Creams Accelerate Skin Barrier Recovery
10/13/2026
Coleen Stern, MA
Creams containing behenic acid (BA) or ceramide (CER) accelerated recovery of experimentally damaged skin, suggesting that both lipid components may support topical formulations designed to restore barrier function.
Creams containing behenic acid (BA) or ceramide (CER) accelerated recovery of experimentally damaged skin, suggesting that both lipid components may support topical formulations designed to restore barrier function.
Creams containing behenic acid...
10/13/2026
The Dermatologist
FDA Alerts
FDA Approves Rhapsido as First Treatment for Symptomatic Dermographism in Adults
10/08/2026
Jessica Garlewicz
On October 7, 2026, the US Food and Drug Administration approved remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, as the first treatment for adults with symptomatic dermographism inadequately controlled by H1...
On October 7, 2026, the US Food and Drug Administration approved remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, as the first treatment for adults with symptomatic dermographism inadequately controlled by H1...
On October 7, 2026, the US Food...
10/08/2026
The Dermatologist
News
GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Risk in Patients With Psoriasis
10/07/2026
Jessica Garlewicz
Glucagon-like peptide-1 receptor agonist treatment was associated with lower all-cause mortality and reduced cardiovascular and psychiatric comorbidity risks among patients with psoriasis and obesity or diabetes.
Glucagon-like peptide-1 receptor agonist treatment was associated with lower all-cause mortality and reduced cardiovascular and psychiatric comorbidity risks among patients with psoriasis and obesity or diabetes.
Glucagon-like peptide-1 receptor...
10/07/2026
The Dermatologist
Smiling woman touching neck
News
Anatomy-Driven Model Aims to Prevent GLP-1 RA–Associated Facial Aging
10/01/2026
Coleen Stern, MA
Researchers propose an anatomy-driven framework for identifying patients at risk for rapid, region-specific facial volume loss and intervening before visible facial aging progresses.
Researchers propose an anatomy-driven framework for identifying patients at risk for rapid, region-specific facial volume loss and intervening before visible facial aging progresses.
Researchers propose an...
10/01/2026
The Dermatologist
dkin
News
Review Reframes Skin Barrier as an Integrated Defense System
09/30/2026
Coleen Stern, MA
The skin barrier functions as an interconnected physical, chemical, immune, and microbial defense system rather than a single structural layer.
The skin barrier functions as an interconnected physical, chemical, immune, and microbial defense system rather than a single structural layer.
The skin barrier functions as an...
09/30/2026
The Dermatologist
Alopecia
FDA Alerts
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
09/28/2026
Riya Gandhi, MA
FDA has expanded the indication for baricitinib (Olumiant) to include adolescents aged 12 years and older with severe alopecia areata, based on results from the Phase 3 BRAVE-AA-PEDS trial.
FDA has expanded the indication for baricitinib (Olumiant) to include adolescents aged 12 years and older with severe alopecia areata, based on results from the Phase 3 BRAVE-AA-PEDS trial.
FDA has expanded the indication...
09/28/2026
The Dermatologist
News
Global Psoriasis Burden Nearly Doubled Over 3 Decades, Economic Costs Reach $149 Billion
09/03/2026
Jessica Garlewicz
Investigators assessed trends in psoriasis cases, effects on quality of life, and associated economic costs.
Investigators assessed trends in psoriasis cases, effects on quality of life, and associated economic costs.
Investigators assessed trends in...
09/03/2026
The Dermatologist
FDA Alerts
FDA Approves Lisraya as First Oral Therapy for Adult Dermatomyositis
08/31/2026
Coleen Stern, MA
For dermatologists and patients, this approval provides a new alternative targeting the JAK-mediated inflammation that damages the muscles and skin in dermatomyositis to control both cutaneous and systemic manifestations.
For dermatologists and patients, this approval provides a new alternative targeting the JAK-mediated inflammation that damages the muscles and skin in dermatomyositis to control both cutaneous and systemic manifestations.
For dermatologists and patients,...
08/31/2026
The Dermatologist
FDA Alerts
FDA Grants Accelerated Approval to Tudriqev for PD-1-Refractory Advanced Melanoma
08/07/2026
Jessica Garlewicz
The US Food and Drug Administration (FDA) has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma.
The US Food and Drug Administration (FDA) has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma.
The US Food and Drug...
08/07/2026
The Dermatologist
roflum
FDA Alerts
FDA Approves Roflumilast Cream 0.3% for Plaque Psoriasis in Children as Young as 2 Years
06/30/2026
Riya Gandhi, MA
The expanded indication makes roflumilast cream 0.3% the first once-daily, steroid-free topical therapy approved for plaque psoriasis in children aged 2 years and older, providing a new long-term treatment option for pediatric patients.
The expanded indication makes roflumilast cream 0.3% the first once-daily, steroid-free topical therapy approved for plaque psoriasis in children aged 2 years and older, providing a new long-term treatment option for pediatric patients.
The expanded indication makes...
06/30/2026
The Dermatologist

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use